

**DEPARTMENT OF WAR**

**Defense Health Agency**

**Intent to Grant an Exclusive License for U.S. Government Co-Owned Inventions**

**AGENCY:** Defense Health Agency, DoW

**ACTION:** Notice.

**SUMMARY:** In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive, royalty-bearing, revocable, license within a field of use.

**ADDRESSES:** Commander, U.S. Army Medical Research and Development Command,  
ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite  
227, Fort Detrick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:** Dr. Rajendra Poudel, Office of Research &  
Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory  
Patent Attorney, (301) 619-7808.

**SUPPLEMENTARY INFORMATION:** In accordance with 35 U.S.C. 209 (e) and 37 CFR  
404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use,  
royalty-bearing, revocable license agreement to U.S. Patent Application 17/792,378, filed on  
January 13, 2021 and Canadian patent 3,167691, issued on November 18, 2025, entitled  
“Fentanyl Haptens for the Preparation of a Fentanyl Vaccine” (co-owned by the Henry Jackson  
Foundation and the National Institute on Drug Abuse/NIH) to ARMR Sciences, having its  
principal place of business at 12 East 49<sup>th</sup> St., New York, New York 10017.

In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made  
of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license

agreement to U.S. Patent 12,472,248, issued on November 18, 2025, entitled “Antibodies Against Fentanyl and Fentanyl Analogs” (co-owned by the National Institute on Drug Abuse/NIH) to ARMOR Sciences, having its principal place of business at 12 East 49<sup>th</sup> St., New York, New York 10017.

Anyone wishing to object to grant of this option can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Director, Office of Research and Technology Applications (see **ADDRESSES**).